Ras al-Khaimah , United Arab Emirates had hepatitis-related HCC, and 59.7% had underlying cirrhosis. After adjustment for confounding factors, we found that all therapeutic modalities were associated with a significant mortality rate reduction with an OS of 63, 42.03, 34.3, and 22.1 months among patients treated with surgery, ablation, local, and systemic therapy, respectively. A restricted analysis of cirrhotic and noncirrhotic patients showed that ablative and local therapy were significantly associated with a longer OS compared to systemic therapy. Conclusion: TNM stage I HCC patients have a favorable prognosis regardless of the type of treatment. Notably, ablative and local therapy significantly improved OS compared to systemic therapy. Center patients' medical records. The Kaplan-Meier method was used to calculate patients' overall survival (OS). Cox regression analysis was used to calculate the estimated hazard ratio and 95% confidence interval of different prognostic factors. Results: Out of 397 patients, 67.5% were males, 42.8%
Introduction
Hepatocellular carcinoma (HCC) represents 90% of the primary liver cancers. Initially, it was considered to be one of the commonest cancers in the developing countries; however, over the last few decades, there has been a significant increase in the incidence of and mortality due to HCC in Europe as well as in the United States [1] . Nowadays, liver cancer is the fifth most common cancer in males, the ninth most common cancer in females, and the second most common cause of cancer-related mortality worldwide [1] . Furthermore, 31 and 54% of HCC cases can be attributed to hepatitis C and B virus infections, respectively [2] . The increasing HCC incidence in the United States has been attributed to a dramatic increase in the prevalence of hepatitis C virus infections in the middle of the last century as well as to hepatitis B virus infections among the immigrants from endemic countries and, in addition, to a rising incidence of metabolic syndrome and nonalcoholic steatohepatitis [3] . In the developing countries, the incidence of HCC is parallel to that of viral hepatitis [4] . Notably, cirrhosis is the most common predisposing factor for HCC development in the Western world with a higher risk if cirrhosis is induced by viral hepatitis as compared to other causes of cirrhosis [2, 5] . Presence or absence of cirrhosis along with tumor characteristics, including vascular invasion and portal vein thrombosis, tumor size, and α-fetoprotein (AFP), are important prognostic indicators in HCC patients that affect treatment decision and outcome [1, [6] [7] [8] .
From 1994 to 2004 , there has been a 40% increase in the mortality rate due to HCC in the United States compared to an 18% reduction in the mortality rate related to other cancers [1] . As HCC prognosis is poor, it is vital to diagnose and treat HCC at an early curable stage [9] [10] [11] . According to Barcelona Clinic Liver Cancer (BCLC) guidelines, resection is the only treatment modality able to cure patients with well-preserved liver function (normal bilirubin levels along with either hepatic venous pressure gradient ≤ 10 mm Hg or platelet count ≥ 100,000) and a solitary lesion with no vascular invasion or extrahepatic metastasis, which is defined, according to the American Joint Committee on Cancer (AJCC) 6th edition, as TNM stage I (T1N0M0) [1, 12] . While surgical resection or transplantation is the treatment of choice for appropriate candidates, different local therapy modalities are considered to be the next appropriate treatment if patients are medically not candidates for surgery. Furthermore, systemic therapy is given to this group of patients if they have a European Cooperative Oncology Group (ECOG) performance status of 1-2 or if they are not candidates for local therapy either due to tumor size or location [13] .
In this study, we aimed to identify the key prognostic factors among TNM stage I HCC patients and to assess the influence of treatment provided on patients' overall survival (OS).
Methods

Study Design and Patients' Characteristics
From January 1992 to December 2011, we identified 397 pathologically or radiologically diagnosed HCC patients with TNM stage I that had been referred to the MD Anderson Cancer Centre. Detailed epidemiological data, HCC risk factors, and clinicopathological characteristics were retrieved from patients' medical records, including age at diagnosis, gender, ethnicity, viral hepatitis, alcohol consumption, cigarette smoking, diabetes mellitus, family history of liver cancer or other cancers, personal history of other cancers, tumor differentiation, presence of underlying liver cirrhosis, performance status, serum AFP levels measured in ng/mL, volume of liver occupied by the tumor, degree of liver dysfunction assessed by Child-Turcotte-Pugh (CTP) classification, and different staging systems, including the BCLC and the Cancer of Liver Italian Program (CLIP) scoring system. Also, we retrieved the initial treatment that patients received and classified it into 5 groups: (1) surgery, i.e., either liver resection or transplant; (2) ablative therapy, including radiofrequency, ethanol injection, and cryoablation; (3) local therapy, including transarterial chemoembolization, hepatic arterial infusion, and local radiotherapy; (4) systemic therapy, i.e., either chemotherapy or targeted therapy, and (5) supportive care or hospice ( Table 1 ). All patients had received treatment based on a multidisciplinary team recommendation. The study was approved by the institutional review board at the MD Anderson Cancer Center.
Statistical Analysis
To analyze our data set, we used both IBM SPSS Statistics for Windows, version 21.0 (IBM, Armonk, NY, USA) and Stata software (version 7.0; Stata Corporation, College Station, TX, USA). Univariate analysis was done using the χ 2 test or the Fisher exact test for categorical variables and the Kruskal-Wallis test for continuous variables. We used Kaplan-Meier analysis to measure the OS defined by the time between the date of diagnosis and the date of death or of the last follow-up. Median OS and 95% confidence intervals (CI) for different risk factors and epidemiological and clinicopathological characteristics were analyzed by the log-rank test. The adjusted hazard ratio (HR) with the 95% CI was calculated by Cox regression analysis to identify the independent prognostic factors among TNM stage I HCC patients after adjustment for several confounding factors. We repeated the same analysis after classifying patients into 2 groups based on the presence or absence of underlying cirrhosis to identify a difference in the influence of treatment in the presence of cirrhosis. A p value <0.05 indicated a statistically significant difference. 
Results
Among 397 TNM stage I HCC patients, the mean age was 65.04 ± 12.5 years, and the majority of patients were above 60 years of age; 268 (67.5%) patients were males and 129 (32.5%) patients were females, with a male to female ratio of 3: 1. Additionally, 260 (65.5%) of our patients were Whites, and 170 (42.8%) had virus-related HCC. 56.4% had a history of alcohol consumption, 59.4% were cigarette smokers, and a family history of other cancers was reported in 58.2%. All patients had a solitary nodule with a mean tumor size of 6.76 ± 4.58 cm. 72.8% of the patients had good to moderate tumor differentiation, 59.7% had underlying liver cirrhosis, 90.5% had an ECOG performance status of 0-2, and 74.6% had AFP levels <400 ng/mL. In 79.1% of the patients, less than 50% of the liver was occupied by the tumor, and CTP score A was reported in 78.6% of the patients. While the majority of the patients had a CLIP score of 0-2 (83.1%), based on the BCLC staging system 52.2% of the patients were considered to have an advanced stage of disease (BCLC stage C-D). Finally, approximately 30% of our patients were treated with different ablative and local therapy approaches, followed by 25.7% who were treated with surgery (either resection or transplantation), while the majority of our patients were treated with both systemic therapy (20.4%) and hospice (22.4%) ( Table 2 ). As the majority of the patients were treated before the Food and Drug Administration (FDA) approval of sorafenib, only 12 patients were treated with sorafenib among the patients treated with systemic therapy.
The Kaplan-Meier curve illustrated that the median OS of all TNM stage I patients was 27 months (95% CI 22.3-31.7) ( Fig. 1 ) . Table 2 shows that there was a significantly shorter OS among patients who had a poorer ECOG performance status, a higher AFP level, >50% of the liver occupied by the tumor, a higher CTP score, a higher CLIP score, and a more advanced BCLC stage. Furthermore, the median OS among surgically treated cases was 63 months (95% CI 43-83) compared to 42.03 months (95% CI 35.2-48.9) in the group treated with ablative therapy, 34.3 months (95% CI 28.3-40.3) in the group treated with local therapy, 22.1 months (95% CI 17.1-27.1) in the group treated with systemic therapy, and 8.1 months (95% CI 5.1-11.1) in the group who received supportive treatment only ( p < 0.0001). Within the group treated with systemic therapy, the median OS of patients treated with sorafenib was compared to patients treated with chemotherapy ( Fig. 2 ) . Although there was no significant difference, which could be due to the small sample size of the sorafenib group, there was a trend for a longer OS among patients treated with sorafenib.
In the multivariate Cox regression analysis, after adjustment for several confounding factors, including age, a Others includes 5-fluorouracil + interferon, capecitabine alone, PIAF (cisplatin, human recombinant α-interferon-2a, doxorubicin, and 5-fluorouracil), FLAP (floxuridine, leucovorin, doxorubicin, and cisplatin), capecitabine with interferon, capecitabine with radiotherapy, doxorubicin alone, 5-fluorouracil with doxorubicin, erlotinib alone, GAP (gemcitabine, doxorubicin, and cisplatin), 5-fluorouracil alone, thalidomide alone, and gemcitabine alone. sex, race, hepatitis status, alcohol consumption, diabetes mellitus, pathology differentiation, underlying cirrhosis, ECOG performance status, AFP level, tumor volume, CLIP and BCLC staging systems, we found that treatment received was the only independent predictor of patients' OS. Surgical intervention and local therapy were associated with a 72% and a 64% reduction in the mortality rate compared to nontreated patients, respectively ( p < 0.0001). Additionally, both systemic and ablation therapy were associated with a 62% reduction in mortality compared to the nontreated group with p values of <0.0001 and 0.002, respectively.
A restricted analysis based on underlying cirrhosis showed that there was a statistically significant difference in the median OS between cirrhotic and noncirrhotic stage I HCC patients based on the received treatment. In the cirrhotic group, the median OS of surgically treated patients was 46.5 months (95% CI 24.7-68.2) with a 70% mortality rate reduction compared to no treatment after adjustment for several confounding factors. Additionally, the median OS for both ablative and local therapy was 41.8 and 35.7 months, respectively. While there was no significant difference in the HR of ablative therapy (HR 0.54, 95% CI 0.26-1.1; p = 0.09) compared to no treat- HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; FHx, family history; ECOG, European Cooperative Oncology Group; AFP, α-fetoprotein; CLIP, Cancer of Liver Italian Program; nd, not detectable; BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care. a Some of the data were not available in the patients' medical records or the staging could not be calculated due to missing parameters, including alcohol drinking (n = 1), diabetes mellitus (n = 4), cigarette smoking (n = 2), FHx of liver cancer (n = 16), FHx of other cancers (n = 16), personal history of cancer (n = 5), pathological differentiation (n = 65), presence of cirrhosis (n = 1), ECOG (n = 4), % of liver tumor involvement (n = 27), CLIP score (n = 35), and first-line treatment (n = 4). b Ablation therapy includes radiofrequency, ethanol injection, and cryoablation. c Local therapy includes transarterial chemoembolization, hepatic arterial infusion, and local radiotherapy and radiofrequency. 8 months) ; it was associated with a 61% mortality rate reduction compared to no treatment ( p = 0.002) ( Table 3 ) . Additionally, among noncirrhotic stage I HCC patients, surgery was still associated with the longest OS (91.3 months) compared to ablative therapy (42.03 months), local therapy (33.6 months), systemic therapy (20.8 months), and hospice (11.4 months; p < 0.0001). Surgical intervention was significantly associated with the highest mortality rate reduction (91%; p < 0.0001), followed by ablative therapy (83%; p = 0.007), local therapy (79%; p < 0.0001), and systemic therapy (60%; p = 0.03) ( Table 4 ) . Table 5 shows that there was no significant difference in the HR of ablative therapy (HR 0.73, 95% CI 0.47-1.15) and of local therapy (HR 0.75, 95% CI 0.54-1.04) as compared to systemic therapy among TNM stage I patients ( p = 0.2 and 0.08, respectively). We achieved the same results when we classified patients based on the underlying cirrhosis; except for patients without cirrhosis, local therapy showed a significant tendency ( p = 0.05).
Discussion
Our study shows that the treatment approach is an independent predictor of survival among TNM stage I HCC patients (T1N0M0), defined as having a solitary HCC lesion with no vascular invasion or extrahepatic metastasis. Variable prognostic outcomes have been reported in patients with HCC, either depending on the involvement of the bile duct, tumor thrombus, cirrhosis, poor liver function, large tumor size, vascular invasion, satellite lesions, etc. Survival rates at 1, 3, and 5 years after hepatic resection among patients with and without bile duct tumor thrombus have been reported to be 92, 77, and 48% and 88, 67 and 52%, respectively [14] . Lang et al. [15] observed 3-and 5-year survival rates of 54 and 39%, respectively, after R0 resection among HCC patients without cirrhosis. Morris-Stiff et al. [16] reported median 1-, 3-, and 5-year OS rates of 80.1, 55, and 37.1%, respectively, among patients who underwent resection. However, in these studies, HCC patients with variable TNM stages were included.
Notably, HCC may develop in the underlying cirrhotic or noncirrhotic liver. However, the presence of cirrhosis is associated with a worse HCC prognosis and a shorter survival. Many previous studies which addressed the prognostic factors in HCC did not classify patients based on the presence or absence of cirrhosis and on the stage of the disease, which led to the inclusion of a heterogeneous group of patients [8] .
In our current study, we focused on TNM stage I HCC patients, and we assessed the prognostic factors in the whole study population, which we reclassified based on the underlying cirrhosis, and we found that tumor resection led to the longest OS in our population when compared to the other treatment modalities; this was still true when we subclassified the study population based on the underlying cirrhosis. a Some of the data were not available in the patients' medical records or the staging could not be calculated due to missing parameters, including alcohol drinking (n = 1), diabetes mellitus (n = 4), cigarette smoking (n = 2), FHx of liver cancer (n = 16), FHx of other cancers (n = 16), personal history of cancer (n = 5), pathological differentiation (n = 65), presence of cirrhosis (n = 1), ECOG (n = 4), % of liver tumor involvement (n = 27), CLIP score (n = 35), and first-line treatment (n = 4).
b Ablation therapy includes radiofrequency, ethanol injection, and cryoablation. c Local therapy includes transarterial chemoembolization, hepatic arterial infusion, and local radiotherapy and radiofrequency. Surgical treatment is considered to be a safe and effective treatment option for elderly HCC patients, especially those without perioperative comorbidities or with controlled comorbidities [17] . In our population, the majority of our patients were above 60 years of age, showing a preponderance of the elderly, and 25.7% of the patients were treated with surgery, i.e., either resection or orthotropic liver transplantation.
While surgery is the main treatment modality able to cure early-stage HCC patients, some patients may not be candidates for surgical approaches either due to a poor performance status or due to associated medical comorbidities. In these situations, patients should be treated either with local therapy, ablative procedures, or systemic therapy. Notably, in our study, the median OS with systemic therapy was significantly shorter than for both ablative and local therapy among the whole studied population even when we classified patients based on the underlying cirrhosis.
Our study had several strengths, including the large number of patients studied over a period of 20 years. We also used TNM staging for our analysis as it is considered to be an independent predictor of postoperative OS in elderly HCC patients [17] . Additionally, our results of a favorable outcome in patients with single tumors and no vascular invasion or extrahepatic metastasis are consistent with recent reports about the good prognosis in this patient population. Furthermore, in our database, all clinicopathological variables were collected in a prospective manner at the time of enrollment, and all treatment history data of the patients were available for retrospective retrieval. However, our study has some limitations. First, the retrospective nature of the analysis was a limitation. Second, among patients treated with systemic therapy, only 12 had been treated with sorafenib, which was approved by the FDA in 2007 to be the only effective systemic HCC therapy associated with a prolongation of OS and now is the standard systemic therapy for unresectable HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; FHx, family history; ECOG, European Cooperative Oncology Group; AFP, α-fetoprotein; nd, not detectable; CLIP, Cancer of Liver Italian Program; BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care. a Some of the data were not available in the patients' medical records or the staging could not be calculated due to missing parameters, including alcohol drinking (n = 1), diabetes mellitus (n = 4), cigarette smoking (n = 2), FHx of liver cancer (n = 16), FHx of other cancers (n = 16), personal history of cancer (n = 5), pathological differentiation (n = 65), presence of cirrhosis (n = 1), ECOG (n = 4), % of liver tumor involvement (n = 27), CLIP score (n = 35), and first-line treatment (n = 4). b Ablation therapy includes radiofrequency, ethanol injection, and cryoablation. c Local therapy includes transarterial chemoembolization, hepatic arterial infusion, and local radiotherapy and radiofrequency. HCC patients with preserved liver function, defined as Child-Pugh class A [1, 18] . Although we had a limited number of patients treated with sorafenib, these patients tended to have a longer OS than patients treated with other systemic therapy modalities. Additionally, systemic therapy induced a higher rate of mortality reduction than no active treatment. Larger prospective studies are warranted to assess the outcome for sorafenib in TNM stage I HCC patients who are not candidates for either surgery or ablative/local approaches in the presence and absence of cirrhosis.
Conclusion
Overall, TNM stage I HCC patients have a favorable prognosis. Our results indicate that surgery is the best treatment modality, followed by ablative and local therapy. While systemic therapy was associated with the shortest OS, it is still a suitable treatment option for patients who are not candidates for both surgery and local treatment. To the best of our knowledge, there are no major studies reporting on the outcome of systemic therapy in TNM stage I HCC patients. Further prospective studies are warranted to understand the impact of sorafenib on early-stage HCC.
